Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$165.70
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,788,464,640.00
EPSttm : 3.01
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$165.70
3.27%
$5.60

Float Short %

10.97

Margin Of Safety %

43

Put/Call OI Ratio

0.47

EPS Next Q Diff

0.03

EPS Last/This Y

4.46

EPS This/Next Y

3.19

Price

171.16

Target Price

214.8

Analyst Recom

1.18

Performance Q

9.46

Relative Volume

1.62

Beta

0.77

Ticker: KRYS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-10KRYS184.110.540.714394
2025-03-11KRYS184.770.550.324520
2025-03-12KRYS178.410.55110.004548
2025-03-13KRYS177.520.620.004765
2025-03-14KRYS179.420.623.004775
2025-03-17KRYS186.830.622.504775
2025-03-18KRYS188.490.640.004841
2025-03-19KRYS188.90.410.046653
2025-03-20KRYS188.880.360.007519
2025-03-21KRYS187.170.380.337919
2025-03-24KRYS194.750.460.064467
2025-03-25KRYS192.140.440.244577
2025-03-26KRYS186.920.46999.994527
2025-03-27KRYS182.750.461.444537
2025-03-28KRYS183.150.472.004571
2025-03-31KRYS179.110.470.144581
2025-04-01KRYS173.830.470.004585
2025-04-02KRYS180.780.470.404592
2025-04-03KRYS177.750.472.104592
2025-04-04KRYS171.320.470.204588
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-10KRYS184.05202.8114.57.58
2025-03-11KRYS184.76202.8110.57.58
2025-03-12KRYS178.52202.8101.07.58
2025-03-13KRYS177.37202.8107.87.58
2025-03-14KRYS179.38202.8111.97.58
2025-03-17KRYS186.89202.8119.27.58
2025-03-18KRYS188.50202.8111.37.58
2025-03-19KRYS189.18202.8110.07.58
2025-03-20KRYS188.61202.8108.57.58
2025-03-21KRYS187.17202.8107.47.58
2025-03-24KRYS194.44202.8118.67.58
2025-03-25KRYS192.30202.8106.67.58
2025-03-26KRYS187.10202.8102.87.58
2025-03-27KRYS182.62202.8103.57.58
2025-03-28KRYS183.92202.8110.77.58
2025-03-31KRYS180.30202.8104.57.58
2025-04-01KRYS174.58202.8102.07.58
2025-04-02KRYS181.00202.8118.07.58
2025-04-03KRYS178.13202.8105.47.58
2025-04-04KRYS171.16202.899.87.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-10KRYS-4.47-0.8613.00
2025-03-11KRYS-4.47-0.8613.00
2025-03-12KRYS-4.47-0.8611.27
2025-03-13KRYS-4.47-0.8611.27
2025-03-14KRYS-4.48-0.8611.26
2025-03-17KRYS-4.48-0.8511.26
2025-03-18KRYS-4.48-0.8511.26
2025-03-19KRYS-4.58-0.8511.22
2025-03-20KRYS-4.58-0.8511.22
2025-03-21KRYS-4.58-0.8511.22
2025-03-24KRYS-4.58-0.8111.22
2025-03-25KRYS-4.58-0.8111.22
2025-03-26KRYS-4.58-0.8110.97
2025-03-27KRYS-4.58-0.8110.97
2025-03-28KRYS-4.58-0.8110.97
2025-03-31KRYS-4.58-0.8210.97
2025-04-01KRYS-4.58-0.8210.97
2025-04-02KRYS-4.58-0.8210.97
2025-04-03KRYS-4.58-0.8210.97
2025-04-04KRYS-4.58-0.8210.97
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.52

Avg. EPS Est. Current Quarter

1.39

Avg. EPS Est. Next Quarter

1.55

Insider Transactions

-4.58

Institutional Transactions

-0.82

Beta

0.77

Average Sales Estimate Current Quarter

99

Average Sales Estimate Next Quarter

108

Fair Value

244.17

Quality Score

79

Growth Score

44

Sentiment Score

64

Actual DrawDown %

22

Max Drawdown 5-Year %

-53.4

Target Price

214.8

P/E

57.33

Forward P/E

15.79

PEG

0.85

P/S

16.99

P/B

5.21

P/Free Cash Flow

41.4

EPS

2.99

Average EPS Est. Cur. Y​

7.58

EPS Next Y. (Est.)

10.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

30.69

Relative Volume

1.62

Return on Equity vs Sector %

-10.4

Return on Equity vs Industry %

2.6

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

0.83

EBIT Estimation

99.8
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading